 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates with a Favorable Safety Profile in Asian Patients: an Integrated Subgroup Analysis of From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
Henry L.Y. Chan1, Ching-Lung Lai2, Jordan Feld3, Nancy Reau4, LingLing Han5, Brian McNabb5, John McNally5, Diana M Brainard5, Graham Foster6, Stuart Roberts7
1The Chinese University of Hong Kong; 2The University of Hong Kong; 3Toronto General Hospital Liver Center, Toronto, ON, Canada; 4Rush University Medical Center, Chicago, IL, USA; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Queen Mary University of London, London, UK; 7The Alfred Hospital Gastroenterology Department, Melbourne, Australia
|
| |
|
|
|
|
|
